These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36210235)

  • 41. The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy.
    Sarıkaya Uzan G; Paketçi C; Günay Ç; Edem P; Özsoy Ö; Hız Kurul S; Yiş U
    Neuropediatrics; 2022 Oct; 53(5):321-329. PubMed ID: 35871521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
    Introna A; Milella G; D'Errico E; Fraddosio A; Scaglione G; Ucci M; Ruggieri M; Simone IL
    Muscle Nerve; 2021 Jun; 63(6):905-909. PubMed ID: 33660868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Modern principles of therapy for patients with spinal muscular atrophy].
    Bofanova NS; Eliseeva AR; Onchina VS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3):34-40. PubMed ID: 36946394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study.
    Stettner GM; Hasselmann O; Tscherter A; Galiart E; Jacquier D; Klein A
    BMC Neurol; 2023 Feb; 23(1):88. PubMed ID: 36855136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nutritional Therapy in Children With Spinal Muscular Atrophy in the Era of Nusinersen.
    Yerushalmy-Feler A; Levy D; Sagi L; Fattal-Valevski A; Shiff YE; Brener A; Cohen S
    J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):e154-e160. PubMed ID: 33492038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients.
    Nuzzo T; Russo R; Errico F; D'Amico A; Tewelde AG; Valletta M; Hassan A; Tosi M; Panicucci C; Bruno C; Bertini E; Chambery A; Pellizzoni L; Usiello A
    Commun Med (Lond); 2023 Feb; 3(1):28. PubMed ID: 36792810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CSF IL-8 Associated with Response to Gene Therapy in a Case Series of Spinal Muscular Atrophy.
    Verma S; Perry K; Razdan R; Howell JC; Dawson AL; Hu WT
    Neurotherapeutics; 2023 Jan; 20(1):245-253. PubMed ID: 36289175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy - A single-center retrospective study.
    Heitschmidt L; Pichlmaier L; Eckerland M; Steindor M; Olivier M; Fuge I; Kölbel H; Hirtz R; Stehling F
    Eur J Paediatr Neurol; 2021 Mar; 31():88-91. PubMed ID: 33711791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters.
    Stolte B; Nonnemacher M; Kizina K; Bolz S; Totzeck A; Thimm A; Wagner B; Deuschl C; Kleinschnitz C; Hagenacker T
    J Neurol; 2021 Dec; 268(12):4667-4679. PubMed ID: 33899154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
    Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
    J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
    Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
    Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy.
    Schafernak KT; Jacobsen JR; Hernandez D; Kaye RD; Perez SE
    Acta Cytol; 2022; 66(1):79-84. PubMed ID: 34515035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy.
    Osmanovic A; Ranxha G; Kumpe M; Müschen L; Binz C; Wiehler F; Paracka L; Körner S; Kollewe K; Petri S; Schreiber-Katz O
    J Neurol; 2020 Aug; 267(8):2398-2407. PubMed ID: 32361837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.